A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients
Open Access
- 30 April 2006
- journal article
- Published by Elsevier in Journal of Hepatology
- Vol. 44 (4), 671-678
- https://doi.org/10.1016/j.jhep.2005.12.011
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- New Kinetic Models for the Hepatitis C Virus *Hepatology, 2005
- International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis CJournal of Hepatology, 2005
- Heterogeneous Virologic Response Rates to Interferon-Based Therapy in Patients with Chronic Hepatitis C: Who Responds Less Well?Annals of Internal Medicine, 2004
- Pharmacokinetics of PeginterferonsSeminars in Liver Disease, 2003
- Current therapy for hepatitis C: pegylated interferon and ribavirinClinics in Liver Disease, 2003
- Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-α Fusion Protein in Cynomolgus MonkeysJournal of Pharmacology and Experimental Therapeutics, 2002
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet, 2001
- The Neutralization of Interferons by Antibody. II. Neutralizing Antibody Unitage and Its Relationship to Bioassay Sensitivity: The Tenfold Reduction UnitJournal of Interferon & Cytokine Research, 2001
- Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α TherapyScience, 1998